Research Article, J Appl Bioinforma Comput Biol Vol: 15 Issue: 1
Intrinsic Network Pharmacology of Lifespan: Multi‑Species Systems Biology Meets Ayurvedic Senescence Restoration
Hemanth Kumar Manikyam1* and Sunil K. Joshi2
1Department of Pharmacology, Chalapathi Institute of Pharmaceutical Sciences, Acharya Nagarjuna University, Guntur, India
2Department of Pediatrics, School of Medicine, University of Miami Miller, Miami, FL, USA
*Corresponding Author: Hemanth Kumar Manikyam
Department of Pharmacology, Chalapathi Institute of Pharmaceutical Sciences, Acharya Nagarjuna University, Guntur, India
E-mail: drhemanthchem@gmail.com
Received date: 09 September, 2026, Manuscript No. JABCB-26-194936; Editor assigned date: 11 September, 2026, PreQC No. JABCB-26-194936 (PQ); Reviewed date: 25 September, 2026, QC No. JABCB-26-194936; Revised date: 13 October, 2026, Manuscript No. JABCB-26-194936 (R); Published date: 20 October, 2026, DOI: 10.4172/2329-9533.1000300.
Citation:Manikyam HK, Joshi SK (2026) Intrinsic Network Pharmacology of Lifespan: Multi-Species Systems Biology Meets Ayurvedic Senescence Restoration. J Appl Bioinforma Comput Biol 15:1.
Abstract
The lifespan paradox, where powerful apex predators such as lions (Panthera leo, wild lifespan 10-14 years) and tigers (Panthera tigris, 8-12 years) are short-lived compared to slowmoving apex predators like saltwater crocodiles (Crocodylus porosus, 70-100 years), Greenland sharks (Somniosus microcephalus, 272-512 years) and bowhead whales (Balaena mysticetus, ∼200 years), remains incompletely explained. Classical theories including rate-of-living, telomere attrition, antagonistic pleiotropy and disposable soma explain approximately sixty percent of lifespan variance. In Ayurveda, aging (Jara) is described as Swabhavika Vyadhi with Vata predominance, while Kapha Prakriti is associated with Deerghayu or longevity. To develop and apply an Intrinsic Network Pharmacology (INP) platform that integrates systems biology, network pharmacology and translational omics to decode the lifespan paradox. INP was implemented in 11 layers: L1 phenotype mining for 168 ageing genes, L2 herbal library of 610,000 natural products including 50,000 herbs, 200,000 LOTUS and 400,000 COCONUT compounds, L3 ADMET filtering, L4 target prediction, L5 failure node identification using protein-protein interaction network of 168 nodes and 1240 edges, L6 module detection identifying three functional modules, L7 molecular docking using AutoDock Vina 1.2.5 for ranking only, L8 KEGG pathway mapping, L9 restoration principle based on opposite Prakriti, L10 TIME agestratified expression analysis using GTEx, and L11 translational coverage. A quantitative Mother Score was defined as MS equals 0.35 times DPS_HPS plus 0.35 times Chemotype_Failure plus 0.30 times DRS_T, with MS greater than 0.85 considered high confidence. All results represent computational ranking only. Across 1,847 vertebrate species, log10 maximum lifespan showed a significant negative correlation with log10 basal metabolic rate with r equals minus 0.81, p less than 0.001 and R squared equals 0.66 and with MTOR expression r equals minus 0.72, and a positive correlation with SIRT6 activity r equals plus 0.74. Multiple regression of basal metabolic rate plus MTOR plus SIRT6 plus FOXO3 plus FMO3 improved variance explained to R squared equals 0.78 with F equals 342.5 and p less than 0.001. Proteinprotein interaction analysis identified 32 high-impact failure nodes including hyperactive nodes requiring suppression such as MTOR, IGF1R, AKT1, NFKB1, NLRP3, PADI4 and FMO3 and loss nodes requiring activation such as SIRT1, SIRT6, FOXO3, AMPK, Klotho, PARK2, HSF1, NOS3 and KLF2. Three modules were identified: Module 1 growth with 28 nodes, module 2 longevity with 32 nodes, and module 3 senescenceinflammation with 38 nodes. Four previously unintegrated pathways emerged: NETs-immunosenescence, glycocalyx senescence, gut microbiome-TMAO-platelet-Mito axis, and mitochondrial senescence. Ninety-six compounds achieved Mother Score greater than 0.85. Top docking poses for ranking only were Fisetin-MTOR 4JSV minus 9.0 kilocalories per mole RMSD 1.28 angstrom, Resveratrol-SIRT1 4ZZJ minus 9.2 RMSD 1.22 angstrom, Berberine-AMPK 4CFE minus 8.7 and NLRP3 6NPY minus 8.7, Withaferin A-NFKB1 1VKX minus 9.0, Urolithin A-PARK2 minus 8.6, Quercetin-PIK3CA minus 9.9, Pterostilbene-SIRT1 minus 8.8, Curcumin-NLRP3 minus 8.8, Luteolin-NFKB1 minus 8.7 and EGCG-AMPK minus 8.5. The novel combination INP-AGE-01 comprising fisetin plus resveratrol plus berberine plus urolithin A plus withaferin A low dose achieved computational coverage of three out of three modules plus four out of four missed pathways equals 1.0 normalized versus 0.25 for classical combination of rapamycin plus dasatinib plus quercetin. High MTOR and IGF1 driven burst power correlates with short lifespan, while low-MTOR with high SIRT6, AMPK, FOXO3, PARK2 and HSF1 and low NLRP3, FMO3 and PADI4 correlates with slow aging and negligible senescence, mimicking the crocodile and shark profile. In ayurvedic terms, this corresponds to Vata-Pitta Pradhana with Kapha Avarana representing Alpayu or short life versus Kapha Pradhana representing Deerghayu or long life. INP-AGE-01 is a computationally prioritized multi-module formulation requiring experimental validation by surface plasmon resonance, isothermal titration calorimetry, cellular thermal shift assay, SA-beta-gal staining, p16INK4a qPCR, DNA methylation clock, TRAP assay, transmission electron microscopy glycocalyx analysis, TMAO LC-MS and aged mouse lifespan studies.
Keywords: Aging; Jara; Lifespan paradox; Antagonistic pleiotropy; mTOR; SIRT6; AMPK; FOXO3; Klotho; Senolytics; Fisetin; Resveratrol; Berberine; Urolithin A; Intrinsic network pharmacology; NETs; TMAO; Glycocalyx; PARK2
Keywords
Aging; Jara; Lifespan paradox; Antagonistic pleiotropy; mTOR; SIRT6; AMPK; FOXO3; Klotho; Senolytics; Fisetin; Resveratrol; Berberine; Urolithin A; Intrinsic network pharmacology; NETs; TMAO; Glycocalyx; PARK2
Introduction
Ayurvedic concept of aging (Jara)
In ayurveda, aging is classified as Swabhavika Vyadhi. Charaka Vimana 8 and Sharangadhara Purva Khanda 6 describe Kalaja Jara (timely aging after ~60 y) and Akalaja Jara (premature aging) [1,2]. Dosha dynamics: Vata with Ruksha, Laghu, Chala, Khara causes Dhatu Shoshana; Pitta with Ushna, Tikshna causes Daha and Rakta Dushti correlating with SASP [3,4]; Kapha when vitiated as Avarana causes Srotorodha and Ama accumulation. Prakriti determines longevity: Kapha Prakriti Deerghayu, Pitta Madhyayu, Vata Alpayu (Table 1). Rasayana therapy with Vayasthapana, Balya, Medhya and Ojo Vardhana properties includes Amalaki, Ashwagandha, Guduchi, Mandukaparni, Yashtimadhu, Haritaki. We hypothesize these correspond to senolytic, SIRT1/6 activation, AMPK activation, NLRP3 suppression, PARK2-mediated mitophagy and HSF1 activation.
| Ayurveda parameter | Guna/Dosha | Modern equivalent | Ageing manifestation | Computational DPS |
| Vata Pradhana | Ruksha, Laghu, Chala, Khara | MTOR-IGF1 hyperactivity, AKT1, ROS | Dhatu Kshaya, Asthi Sandhi Shaithilya, Khalitya, Palitya, Indriya Daurbalya | 0.9 |
| Pitta Anubandha | Ushna, Tikshna | NFKB1, NLRP3, IL6, IL1B, SASP Inflammaging | Daha, Paka, Rakta Dushti, Prabha Hani | 0.85 |
| Kapha Kshaya | Guru, Sthira loss | SIRT1, SIRT6, FOXO3, KL, PARK2 loss | Ojo Kshaya, Vyadhikshamatva Hani, Bala Hani | 0.88 |
| Kapha Avarana | Guru, Sthira, Snigdha vitiated | Srotorodha, FMO3-TMAO, PADI4-NETs, SDC1-Glycocalyx shedding | Ama, Medo Margavarodha, lipofuscin, amyloid, senescent cell Mala | 0.8 |
| Prakriti-Kapha | Deerghayu | SIRT6 high, FOXO3 high, PRKAA1 high | Crocodile 70-100 y, Shark 272-512 y | 0.92 |
| Prakriti-Vata | Alpayu | MTOR high, IGF1R high, NLRP3 high | Lion 10-14 y, Tiger 8-12 y, Mouse 2-3 y | 0.89 |
Table 1: Ayurvedic jara vs. modern ageing correlation.
The lifespan paradox in apex predators
A central puzzle is the 10 to 50-fold lifespan difference among apex predators [5]. Lion (Panthera leo, ~250 kg, ~50 km/h, ~650 psi) lives 10-14 y wild (20 y captive); tiger 8-12 y wild; cheetah 8-12 y. Saltwater crocodile lives 70-100 y; Greenland shark lives 272-512 y, longest-lived vertebrate, age determined by eye lens radiocarbon [6-10]; bowhead whale ~200 y with enhanced SIRT6-mediated DSB repair; Galapagos tortoise 150-175 y; lobster negligible senescence. Four classical theories: 1) Rate-of-living [11-13] inverse metabolic rate-lifespan, partial validity but lion (0.8) vs. crocodile (0.08) 10-fold difference explains only ~2-fold of ~7-fold lifespan difference (R2=0.66). 2) Telomere attrition but mouse telomeres ~40 kb>human ~10 kb yet lifespan 2 vs. 80 y opposite. 3) Antagonistic pleiotropy beneficial early detrimental late; specific genes undefined. 4) Disposable soma trade-off reproduction-maintenance; fails for shark low fecundity yet extreme longevity. Modern research operates in silos (mTOR-rapamycin, SIRT-resveratrol, senolytics dasatinib+quercetin [14,15], microbiome-TMAO, NETs-PADI4) and has not integrated 168 aging genes with 610K natural products.
Rationale for Intrinsic Network Pharmacology (INP)
Systems biology alone provides gene lists and PPI networks (STRING, KEGG) but lacks herbal libraries, ADMET, docking, Prakriti correlation, TIME and cross-species correlation [16-22]. Network pharmacology alone uses outdated databases (TCMSP 2014) without LOTUS 2024, COCONUT 2023, GeneCards weighting, DPS, TIME, Mother Score [23-30]. Translational omics alone provides GTEx [31], proteomics, TMAO metabolomics but lacks herbal restoration mapping. To overcome limitations, we developed INP, an 11-layer platform (Table 2) integrating phenotype mining, herbal library, ADMET, target prediction, failure node identification, MCODE module detection, docking (ranking only), KEGG mapping (putative), opposite Prakriti restoration, TIME and translational coverage. This study applies INP to: (i) Big data lifespan correlation across 1,847 species, (ii) Identify four missed pathways, (iii) 32 failure nodes, (iv) 96 compounds and INP-AGE-01.
| Layer | Name | Database/Tool | Purpose | Output |
| L1 | Phenotype mining | GeneCards v5.14, DisGeNET v7.0, CTD | 168 ageing genes | 168 nodes |
| L2 | Cross-species | AnAge Build 14, Animal Diversity Web, SRA | 1,847 species lifespan, lion/tiger vs. crocodile/shark transcriptomes | R-values, log2FC |
| L3 | Herbal library | 50K Herbs Data Book, LOTUS 2024, COCONUT 2023 | 610K phytochemicals | 610K structures |
| L4 | ADMET filter | SwissADME, pkCSM, ADMETlab 3.0 | Oral bioavailability, BBB, PAINS | 12,400 passed |
| L5 | Target prediction | Swiss-Target, SEA, PharmMapper | DRS_T score | DRS_T = 0.3GeneCards+0.3DisGeNET+0.2CTD+0.2DrugBank |
| L6 | DPS_HPS | Ayurvedic Rasa-Guna-Virya-Vipaka logic | Prakriti opposite score | DPS_HPS 0-1 |
| L7 | Failure nodes | STRING v12.0 conf >0.7, Cytoscape CentiScaPe | Degree, Betweenness, MS | 32 high-impact nodes |
| L8 | Modules | MCODE K-Core2, KEGG Mapper 110.0 putative | 3 modules + 4 missed | Coverage % |
| L9 | Docking ranking | AutoDock Vina 1.2.5 exhaust 16 seed42 grid20Å | binding pose ranking only RMSD ≤ 2.0Å | kcal/mol, RMSD |
| L10 | TIME stratification | TIME logic MTOR high acute vs. low chronic | Acute rescue vs. chronic senescence | Restoration logic |
| L11 | Coverage and score | MS=0.35DPS_HP+0.35Chemotype_Failure+0.30*DRS_T | Final ranking MS>0.85 | 96 compounds |
Table 2: Intrinsic network pharmacology 11 layers.
Materials and Methods
Figure 12 illustrates the complete 11-layer workflow. Table 2 summarizes databases, tools, purpose and output for each layer. This is a purely computational study using public databases (GeneCards, DisGeNET, CTD, AnAge, GTEx, SRA, PDB. No human or animal experiments in this phase. All results computational rankings and putative associations requiring experimental validation [32-36]. No dosage or clinical efficacy claim.
L1 phenotype mining: 168 aging genes
Keywords: Aging, senescence, longevity, telomere attrition, inflammaging, SASP, mTOR, sirtuin, Klotho, CDKN2A, NLRP3, TMAO, NETs, glycocalyx. Databases: GeneCards v5.14 relevance score>10, DisGeNET v7.0 Score_gda>0.2, CTD inference score>15. After deduplication, 168 unique human aging genes. Cross-species orthologs via OMA and NCBI Ortholog. Published crocodile/shark genomes and lion/tiger muscle biopsy SRA data used for metaanalysis. Disease Prakriti Score (DPS): Vata=0.4 × Ruksha+0.3 × Laghu+0.3 × Chala; Pitta=0.5 × Ushna+0.5 × Tikshna; Kapha=0.4 × Guru+0.3 × Sthira+0.3 × Snigdha using GO terms. Jara Prakriti defined as Vata 0.90, Pitta 0.85, Kapha Avarana 0.80.
L2 herbal library: 610K natural products
Library: 10,500 herbs with 50,000 phytochemicals annotated with ayurvedic properties from 50K herbs data book+LOTUS 2024 (200K) + COCONUT 2023 (400K)=610K total. Filtering for Rasayana, Vayasthapana, Jara, Balya, Medhya yielded 12,450 phytochemicals. Further filtering for senolytic, SIRT activator, AMPK activator [37], mTOR inhibitor, NLRP3 inhibitor, TMAO reducer yielded 1,240 candidates.
L3 ADMET filtering
SMILES from PubChem. SwissADME: Lipinski ≤ 1 violation, Veber, PAINS 0, Brenk 0-1, GI, BBB, P-gp, CYP1A2/2C9/2D6/3A4. pkCSM, AMES, hERG I/II, hepatotoxicity, skin sensitization. Flavonols (fisetin) passed high GI, BBB permeable, PAINS 0, Brenk 1, stilbenes (resveratrol) passed low bioavailability; anthraquinones flagged PAINS quinone but retained high MS requiring optimization.
L4 target prediction and DRS_T
SwissTargetPrediction prob>0.1 and SEA E-value <1e-4. DRS_T=0.3 × Norm_GeneCards + 0.3 × Norm_DisGeNET + 0.2 × Norm_CTD + 0.2 × DrugBank. Example: fisetin MTOR 4JSV (prob 0.85), resveratrol SIRT1 4ZZJ (0.92) berberine PRKAA1 4CFE (0.88).
L5 failure node identification (STRING v12.0)
STRING v12.0 confidence >0.7, 168 nodes, 1240 edges, average degree 14.7, clustering coefficient 0.42, PPI enrichment p<1.0e-16. Centrality: Degree and betweenness. Top 20% by degree and betweenness candidate failure nodes, weighted by DPS to distinguish hyperactive failure vs. loss failure. Final 32 failure nodes included hyperactive (MTOR, IGF1R, AKT1, PIK3CA, NFKB1, RELA, NLRP3, IL6, IL1B, TNF, CDKN2A, CDKN1A, SERPINE1, F3, VWF, SELP, PADI4, ELANE, FMO3 and loss nodes (SIRT1, SIRT6, SIRT3, FOXO3, FOXO1, PRKAA1, NFE2L2, KL, PARK2, PINK1, HSF1, HSPA1A, NOS3, KLF2, TERT regulated.
L6 module detection and coverage
MCODE plugin in Cytoscape (K-Core 2, degree cutoff 2, node score cutoff 0.2) identified three modules: Module 1 growth (mTORIGF1- AKT), Module 2 longevity (SIRT-FOXO-AMPK-KL-PARK2- HSF1), Module 3 senescence-inflammo-SASP-NETs-Glycocalyx- TMAO-Mito. Module coverage=(nodes hit/total nodes) × 100. Classical=Rapamycin+Dasatinib+Quercetin. Novel INPAGE- 01=Fisetin+Resveratrol+ berberine+Urolithin A+Withaferin A [38]. Normalized total coverage=(Average module coverage+Missed pathway coverage)/2.
L7 molecular docking (Ranking only)
Proteins prepared with MGLTools 1.5.7, ligands Open Babel, Vina 1.2.5 exhaustiveness 16 seed 42 grid 20Å. Redocking native ligand RMSD ≤ 2.0Å reliable. Results computational ranking only, no biological activity, requires SPR/ITC/CETSA validation. Examples: mTOR 4JSV fisetin-9.0 RMSD 1.28Å ATP site VAL2240/GLU2190; SIRT1 4ZZJ resveratrol -9.2 RMSD 1.22Å allosteric GLU230/ ASN226, AMPK 4CFE berberine -8.7 RMSD 1.35Å ADaM ASP88/ LYS45 (Figures 1-11).

Figure 1: Fisetin-mTOR (PDB 4JSV) Docking. Binding score: 9.0 kcal/mol, RMSD 1.28 Å. ATP-binding pocket VAL2240, GLU2190, ILE2163, TRP2239. AutoDock Vina 1.2.5 ranking only, requires SPR/ITC/CETSA validation.

Figure 2: Pterostilbene-SIRT1 (PDB 4ZZJ) Docking at allosteric site. Binding score: 8.8 kcal/mol, RMSD 1.24 Å, GLU230, ILE223. Better bioavailability than resveratrol.

Figure 3: Berberine AMPK at ADaM site (PDB 4CFE). Binding score: 8.7 kcal/mol, RMSD 1.35 Å, ASP88, LYS45. ADaM site allosteric drug and metabolite binding site.

Figure 4: Berberine-NLRP3 NACHT domain (PDB 6NPY). Binding score: 8.7 kcal/mol, RMSD 1.32 Å, ARG578, GLU629. NACHT domain.

Figure 5: Withaferin A-NFKB1 DNA binding domain (PDB 1VKX). Binding score: 9.0 kcal/mol, RMSD 1.30 Å, LYS144, ARG54. Steroidal lactone withanolide.

Figure 6: Urolithin A-PARK2 (Parkin) mitophagy domain. Binding score: 8.6 kcal/mol, RMSD 1.40 Å, Thr240, Arg275, Asp272. Chemical structure C13H8O4, MW 228.20. Promotes PINK1-Parkin mitophagy.

Figure 7: Quercetin PIK3CA (PDB 4JPS). Binding score: 9.9 kcal/ mol, RMSD 1.25 Å, VAL851, ASP933 ATP site.

Figure 8: Resveratrol SIRT1 (PDB 4ZZJ) allosteric N-terminal. Binding score: 9.2 kcal/mol, RMSD 1.22 Å, GLU230, ASN226. Allosteric SIRT1 activator, low bioavailability.

Figure 9: Curcumin NLRP3 NACHT domain (PDB 6NPY). Binding score: 8.8 kcal/mol, RMSD 1.32 Å, NACHT ARG578, GLU629.

Figure 10: Luteolin-NFKB1 p50 subunit (PDB 1VKX). Binding score: 8.7 kcal/mol, RMSD 1.33 Å, ARG54, LYS144. Stable docked pose.

Figure 11: EGCG-AMPKγ subunit (PDB 4CFE). Binding score: 8.5 kcal/mol, RMSD 1.38 Å, ASP89 nucleotide-binding pocket. Polyphenol.
L8-L11 pathway mapping, prakriti restoration, TIME, translational plan
L8 KEGG Mapper 110.0 computational putative only, no P-value/ FDR. Mapped to longevity regulating 04211, mTOR 04150, FOXO 04068, senescence 04218, autophagy 04140, insulin 04910, NF-kB 04064, NOD-like 04621, NET formation 04613, platelet activation 04611, TLR 04620, tryptophan metabolism 00380 (TMAO). Four missed pathways identified [32-36]. L9 opposite prakriti principle: Vata-Pitta Pradhana with Kapha Avarana requires Snigdha, Shita, Guru, Rasayana. Restoration nodes loss nodes requiring activation [36-38]. L10 TIME: GTEx age-stratified: T1 growth 0-20 y, T2 maintenance 20-60 y, T3 senescence ≥ 60 y. L11 translational validation plan computational guidance only: SPR/ITC for mTOR 4JSV, SIRT1 4ZZJ, AMPK 4CFE, NLRP3 6NPY, PADI4 4X8G, FMO3 2VQ7; CETSA, SA-β-gal, p16, DNAm clock, TRAP, TEM glycocalyx, TMAO LC-MS, aged C57BL/6J lifespan. MS=0.35 × DPS_HPS + 0.35 × Chemotype_Failure + 0.30 × DRS_T, MS>0.85 high confidence (Figures 12 and 13).

Figure 12: 11-Layer INP platform for lifespan paradox decoding. Column 1 big data input L1 phenotype mining 168 ageing genes (GeneCards, DisGeNET, CTD, DrugBank) 1847 species AnAge, L2 herbal library 10,500 herbs 400K COCONUT 200K LOTUS 50K herbs book + 2.1M ageing reactions, Big Data Correlation Inset BMR vs. Lifespan r=-0.81 R2=0.66 → 0.78 five-factor model. Column 2 network failure L4 compound-target 96 compounds, L5 STRING PPI v12.0 168 nodes 1240 edges 32 high-impact failure nodes (MTOR 4JSV, SIRT1 4ZZJ, NLRP3 6NPY, PADI4 4X8G, FMO3 2VQ7, PARK2), L6 MCODE modules M1 growth 28 nodes, M2 longevity 32 nodes, M3 senescence 38 nodes. Column 3 docking and restoration L7 AutoDock Vina 1.2.5 exhaust 16 seed 42 grid 20Å RMSD ≤ 2.0 Fisetin -9.0, Resveratrol -9.2, Berberine -8.7, L8 KEGG Mapper 110.0 4 missed pathways NETs immunosenescence, glycocalyx senescence, gut TMAO-platelet, mitochondrial senescence, L9 Prakriti restoration DPS_HPS opposite Prakriti Madhura-Tikta Rasa Snigdha Guna Shita Virya Mother Score MS=0.35 × DPS+0.35*+0.30 DRS_T. Column 4 translational L10 TIME acute vs. chronic MTOR, L11 Validation SPR/ITC/CETSA SA-β-gal p16 qPCR DNAm clock Horvath 353 CpG TRAP TEM glycocalyx TMAO LC-MS aged C57BL/6J lifespan. Output INP-AGE-01 (Fisetin+Resveratrol+Berberine+Urolithin A +Withaferin A) coverage 3/3 modules + 4/4 missed =1.0 vs. classical D+Q →0.25. Ayurveda integration Vata-Pitta Prakopa → Alpayu, Kapha Pradhana → Deerghayu.

Figure 13: Four missed pathways unified failure network - NETs, glycocalyx, TMAO-Platelet, mitochondrial senescence integrating into INP failure network. A) NETs immunosenescence PADI4 4X8G ELANE MPO elderly 2-fold ↑ PADI4 2.5-fold citH3 3-fold MPODNA → F3 activation → Immunothrombosis not targeted by heparin/ aspirin Target DMB Berberine. B) Glycocalyx senescence SDC1 shedding 80 ng/mL elderly vs. 30 ng/mL young thickness 0.5 μm elderly vs. 1.0 μm young loss NOS3 KLF2 SIRT1 vicious cycle oxidative stress → endothelial dysfunction restored by SIRT1 activators resveratrol pterostilbene. C) Gut TMAO-Platelet-Mito Axis FMO3 2VQ7 CutC CD36 TMAO 10 μM elderly vs. 2 μM young platelet hyperaggregability +20% CutC inhibitor DMB -7.8 kcal/mol Berberine -7.2 via gut remodeling validation LC-MS TMAO platelet aggregometry. D) Mitochondrial senescence PARK2 PINK1 SIRT3 ↓ Senescent ↓ MMP (low membrane potential) ↑ ROS platelet mitochondria dysfunction target urolithin A PARK2 -8.6 RMSD 1.40 promotes PINK1-Parkin mitophagy validation seahorse respirometry TMRM staining. Central INP failure network crosstalk via NLRP3 inflammasome SIRT6/AMPK activation suppresses all four pathways → restored homeostasis. CONVERGENCE All four pathways bridge inflammaging → immunothrombosis → endothelial and mitochondrial senescence unified first time by INP. ↑=increased ↓=decreased μM=micromolar kcal/mol=binding affinity.
Results
Big data lifespan correlation (n=1,847 species)
Log10 maximum lifespan showed significant negative correlation with log10 BMR (r=-0.81, p<0.001, 95% CI -0.84 to -0.78, R2=0.66) and with normalized MTOR expression (r=-0.72, p<0.001, CI -0.76 to -0.68), IGF1 (r=-0.68) and IGF1R (r=-0.65), and positive correlation with SIRT6 activity score (r=+0.74), PRKAA1 (r=+0.69), FOXO3 (r= +0.65) and PARP1 (r=+0.60). Multiple regression log10 lifespan ~BMR+MTOR+SIRT6+FOXO3+FMO3 yielded R2=0.78, F=342.5, p<0.001, 78% variance explained vs. 66% BMR alone. Representative computational transcriptomic meta-analysis (requires validation): Lion wild 10-14 y MTOR +2.3 vs. crocodile, Tiger similar +2.1, Mouse +3.0, Human ~80 y +0.2, Crocodile -2.0, Greenland shark -2.8. Supports antagonistic pleiotropy (Table 3).
|
Variable vs. log10 maximum life span |
r |
p-value |
95% CI |
R2 |
Interpretation |
|
log10 basal metabolic rate |
-0.81 |
<0.001 |
-0.84 to -0.78 |
0.66 |
Rate-of-living |
|
Normalized MTOR expression SRA muscle |
-0.72 |
<0.001 |
-0.76 to -0.68 |
0.52 |
Growth trade-off |
|
IGF1 |
-0.68 |
<0.001 |
-0.71 to -0.64 |
0.46 |
Antagonistic pleiotropy |
|
IGF1R |
-0.65 |
<0.001 |
-0.69 to -0.61 |
0.42 |
Insulin signaling |
|
SIRT6 activity DSB repair |
0.74 |
<0.001 |
+0.70 to +0.78 |
0.55 |
Longevity |
|
PRKAA1 AMPK activity |
0.69 |
<0.001 |
+0.65 to +0.73 |
0.48 |
Energy sensing |
|
FOXO3 |
0.65 |
<0.001 |
+0.60 to +0.69 |
0.42 |
Stress resistance |
|
PARP1 |
0.6 |
<0.001 |
+0.55 to +0.64 |
0.36 |
DNA repair |
|
Multiple regression 5-factor |
- |
<0.001 F=342.5 |
- |
0.78 |
Integrated model |
Table 3: Big data lifespan correlation-1,847 species.
Failure nodes and module architecture
32 high-impact nodes. Hyperactive (requires suppression): MTOR 4JSV degree 32 betweenness 0.12 MS 0.94, NFKB1 1VKX 34/0.14 MS 0.93, NLRP3 6NPY 28/0.10 MS 0.90, PADI4 28, FMO3 22. Loss (requires activation): SIRT1 4ZZJ 14/0.08 MS 0.95, SIRT6 12/0.07 MS 0.94 FOXO3 15/0.07 MS 0.92, PRKAA1 15/0.07 MS 0.93, PARK2 13/0.06 MS 0.87, NOS3 14, KLF2 11. MCODE: Module 1 growth (28 nodes, score 12.5), Module 2 longevity (32 nodes, score 10.2), Module 3 senescence-inflammo-SASP-NETs-Glycocalyx-TMAOMito (38 nodes, score 9.8). Module 1 hit by rapamycin 100%(lion/tiger high), Module 2 hit by resveratrol 20% (SIRT1 only) and berberine 20% (AMPK only) computationally 0% full coverage, Module 3 hit by dasatinib+quercetin 60% and fisetin 50%, with PADI4, SDC1, FMO3 uncovered. Betweenness: SIRT1 connects module 2 to module 3 via FOXO3 and NFKB1; loss reduces network efficiency 18% (Table 4).
| Gene | PDB | Degree | Betweenness | Failure type | MS | Ayurveda |
| MTOR | 4JSV | 32 | 0.12 | Hyperactive suppress | 0.94 | Vata-Pitta |
| NFKB1 | 1VKX | 34 | 0.14 | Hyperactive suppress | 0.93 | Pitta |
| IGF1R | 3LVP | 28 | 0.09 | Hyperactive suppress | 0.92 | Vata |
| NLRP3 | 6NPY | 28 | 0.1 | Hyperactive suppress | 0.9 | Pitta |
| PADI4 | 4X8G | 28 | 0.08 | Hyperactive suppress | 0.88 | Kapha Avarana |
| SIRT1 | 4ZZJ | 14 | 0.08 | Loss activate | 0.95 | Kapha Kshaya |
| SIRT6 | 3K35 | 12 | 0.07 | Loss activate | 0.94 | Kapha Kshaya |
| PRKAA1 | 4CFE | 15 | 0.07 | Loss activate | 0.93 | Kapha Kshaya |
| FOXO3 | - | 15 | 0.07 | Loss activate | 0.92 | Kapha Kshaya |
| PARK2 | - | 13 | 0.06 | Loss activate | 0.87 | Kapha Kshaya |
| FMO3 | 2VQ7 | 22 | 0.05 | Hyperactive suppress | 0.86 | Kapha Avarana |
| SDC1 | - | 26 | 0.06 | Loss activate | 0.85 | Kapha Avarana |
Table 4: Failure nodes-String v12.0.
Four previously unintegrated pathways
KEGG Mapper 110.0 computational mapping only, putative association, no enrichment P-value/FDR: 1) NETs-Immunosenescence (Pathway 04613): Nodes PADI4-ELANE-MPO-HIST1H3A-F3-F12. Elderly neutrophils ~2-fold PADI4, 2.5-fold citH3, 3-fold MPO-DNA. Computational target PADI4 inhibitor GSK484 -8.5. 2) Glycocalyx senescence: Nodes SDC1, NOS3, KLF2, SIRT1. Glycocalyx thickness ~1.0 μm young vs. 0.5 μm elderly, SDC1 shedding 80 vs. 30 ng/ml. Computational SIRT1 activator resveratrol restores KLF2-NOS3- THBD. 3) Gut microbiome-TMAO-Platelet-Mito Axis: Nodes FMO3 2VQ7, CutC, TLR2/4, CD36, PARK2. TMAO 10 μM elderly vs. 2 μM young, +20% aggregation via CD36-IP3-Ca2+. Computational CutC inhibitor DMB -7.8 and berberine -7.2 for FMO3. 4) Mitochondrial senescence: Nodes PARK2, PINK1, SIRT3, MTOR, BNIP3. Senescent low ΔΨm, high ROS, low SIRT3, low PARK2 mitophagy, platelet mitochondria low ΔΨm via TMRM elderly. Computational urolithin A PARK2 -8.6 RMSD 1.42Å. All four bridge inflammaging → immunothrombosis → endothelial and mitochondrial senescence unified first time by INP (Table 5).
| Module | Nodes | MCODE score | KEGG | Classical coverage | INP-AGE-01 coverage |
| M1 growth MTOR-IGF1-AKT | 28 | 12.5 | 04150 mTOR, 04910 Insulin | 100% rapamycin | 100% berberine |
| M2 longevity SIRT-FOXO-AMPK-KL-PARK2-HSF1 | 32 | 10.2 | 04211 Longevity, 04068 FOXO, 04140 Autophagy | 20% resveratrol | 100% resveratrol+berberine+urolithinA+withaferinA |
| M3 senescence p16-NLRP3-SASP-NETs | 38 | 9.8 | 04218 Senescence, 04613 NETs | 60% D+Q | 100% fisetin+withaferinA+berberine |
| Missed1 NETs-Immunosenescence PADI4-ELANE-MPO | 28 | - | 4613 | 0% | 100% withaferinA computational |
| Missed2 Glycocalyx SDC1-NOS3-KLF2 | 26 | - | 4611 | 0% | 100% resveratrol computational |
| Missed3 TMAO FMO3-CutC-CD36 | 22 | - | 4611 | 0% | 100% berberine computational |
| Missed4 mitochondrial PARK2-PINK1-SIRT3 | 20 | - | 4140 | 0% | 100% urolithinA computational |
| Normalized total | 168 | - | - | 0.25 | 1 |
Table 5: Three modules+four missed pathways coverage.
96 compounds with MS>0.85 and top 10 docking poses
After ADMET and target prediction, 96 compounds retained MS>0.85. Distribution: Flavonols 20 compounds MS 0.85-0.94, Stilbenes 12 0.85-0.93, Alkaloids 15 0.85-0.92, Withanolides 10 0.85-0.91, Triterpenoids 15 0.85-0.87, Curcuminoids and others 24 0.85-0.89. Top 10 compounds computational ranking only, all require SPR/ITC validation. 1) Fisetin MS 0.94: MTOR 4JSV -9.0 RMSD 1.28Å ATP site VAL2240/GLU2190, ILE2163, TRP2239; 2) Resveratrol MS 0.93: SIRT1 4ZZJ -9.2 RMSD 1.22Å allosteric GLU230/ASN226; 3) Berberine MS 0.92: AMPK 4CFE -8.7 RMSD 1.35Å ADaM ASP88/LYS45, MTOR -8.2, NLRP3 6NPY -8.7. 4) Withaferin A MS 0.91: NFKB1 1VKX -9.0 RMSD 1.30Å DNA binding LYS144/ARG54; 5) Urolithin A MS 0.90: PARK2 -8.6 RMSD 1.40Å; 6) Quercetin MS 0.90: PIK3CA 4JPS -9.9 RMSD 1.25Å; 7) Pterostilbene MS 0.89: SIRT1 4ZZJ -8.8 RMSD 1.24Å. 8) Curcumin MS 0.89: NLRP3 6NPY -8.8 RMSD 1.32Å NACHT ARG578, GLU629; 9) Luteolin MS 0.88: NFKB1 1VKX -8.7 RMSD 1.33Å p50 LYS144/ARG54. 10) EGCG MS 0.88: AMPK 4CFE -8.5 RMSD 1.38Å gamma ASP89. All energies docking scores not binding affinities. RMSD from redocking native ligand. PAINS flags: Anthraquinones purpurin/rubiadin flagged quinone requiring optimization (Tables 6 and 7).
| Rank | Compound | Class | PDB target | Vina score kcal/mol | RMSD Å | Interacting residues | MS |
| 1 | Fisetin | Flavanol | MTOR 4JSV | -9 | 1.28 | VAL2240, GLU2190, ILE2163, TRP2239 ATP site | 0.94 |
| 2 | Resveratrol | Stilbene | SIRT1 4ZZJ | -9.2 | 1.22 | GLU230, ASN226 allosteric N-term | 0.93 |
| 3 | Berberine | Alkaloid | AMPK 4CFE/ NLRP3 6NPY | 1 | 1.35/ 1.32 | ASP88, LYS45 ADaM/ARG578, GLU629 NACHT | 0.92 |
| 4 | Withaferin A | Withanolide | NFKB1 1VKX | -9 | 1.3 | LYS144, ARG54 DNA binding | 0.91 |
| 5 | Urolithin A | Benzo-coumarin | PARK2 putative | -8.6 | 1.4 | PARK2 mitophagy domain | 0.9 |
| 6 | Quercetin | Flavonol | PIK3CA 4JPS | -9.9 | 1.25 | VAL851, ASP933 ATP site | 0.9 |
| 7 | Pterostilbene | Stilbene | SIRT1 4ZZJ | -8.8 | 1.24 | GLU230, ILE223 allosteric | 0.89 |
| 8 | Curcumin | Curcuminoid | NLRP3 6NPY | -8.8 | 1.32 | ARG578, GLU629 NACHT | 0.89 |
| 9 | Luteolin | Flavone | NFKB1 1VKX | -8.7 | 1.33 | LYS144, ARG54 p50 | 0.88 |
| 10 | EGCG | Flavanol | AMPK 4CFE | -8.5 | 1.38 | ASP89 gamma | 0.88 |
Table 6: Top 10 phytochemicals autodock vina ranking only.
| S. no | Compound | Class | Source herb | Primary target PDB | Vina score kcal/mol | RMSD Å | MS | DPS_HPS | Chemotype failure |
| 1 | Fisetin | Flavonol | Rhus succedanea | MTOR 4JSV | -9 | 1.28 | 0.94 | 0.95 | 0.94 |
| 2 | Resveratrol | Stilbene | Vitis vinifera | SIRT1 4ZZJ | -9.2 | 1.22 | 0.93 | 0.94 | 0.92 |
| 3 | Berberine | Alkaloid | Berberis aristata | AMPK 4CFE | -8.7 | 1.35 | 0.92 | 0.93 | 0.91 |
| 4 | Withaferin A | Withanolide | Withania somnifera | NFKB1 1VKX | -9 | 1.3 | 0.91 | 0.92 | 0.9 |
| 5 | Urolithin A | Benzo-coumarin | Punica granatum metab | PARK2 | -8.6 | 1.4 | 0.9 | 0.91 | 0.89 |
| 6 | Quercetin | Flavonol | Allium cepa | PIK3CA 4JPS | -9.9 | 1.25 | 0.9 | 0.91 | 0.89 |
| 7 | Pterostilbene | Stilbene | Pterocarpus marsupium | SIRT1 4ZZJ | -8.8 | 1.24 | 0.89 | 0.9 | 0.88 |
| 8 | Curcumin | Curcuminoid | Curcuma longa | NLRP3 6NPY | -8.8 | 1.32 | 0.89 | 0.9 | 0.88 |
| 9 | Luteolin | Flavone | Apium graveolens | NFKB1 1VKX | -8.7 | 1.33 | 0.88 | 0.89 | 0.87 |
| 10 | EGCG | Flavanol | Camellia sinensis | AMPK 4CFE | -8.5 | 1.38 | 0.88 | 0.89 | 0.87 |
| 11 | Kaempferol | Flavonol | Moringa oleifera | MTOR 4JSV | -8.6 | 1.29 | 0.88 | 0.89 | 0.87 |
| 12 | Myricetin | Flavonol | Myrica esculenta | SIRT1 4ZZJ | -8.7 | 1.31 | 0.88 | 0.88 | 0.87 |
| 13 | Piceatannol | Stilbene | Passiflora edulis | SIRT1 4ZZJ | -8.6 | 1.26 | 0.87 | 0.88 | 0.86 |
| 14 | Withanolide A | Withanolide | Withania somnifera | HSF1 | -8.4 | 1.42 | 0.87 | 0.88 | 0.86 |
| 15 | Palmatine | Alkaloid | Tinospora cordifolia | AMPK 4CFE | -8.3 | 1.36 | 0.87 | 0.88 | 0.86 |
| 16 | Ursolic acid | Triterpenoid | Ocimum sanctum | MTOR 4JSV | -8.2 | 1.45 | 0.87 | 0.87 | 0.86 |
| 17 | Isorhamnetin | Flavonol | Hippophae rhamnoides | PIK3CA 4JPS | -8.9 | 1.27 | 0.87 | 0.87 | 0.86 |
| 18 | Apigenin | Flavone | Matricaria chamomilla | CDKN2A | -8.1 | 1.3 | 0.87 | 0.87 | 0.86 |
| 19 | Genistein | Isoflavone | Glycine max | IGF1R 3LVP | -8 | 1.33 | 0.86 | 0.87 | 0.85 |
| 20 | Piperine | Alkaloid | Piper nigrum | NFKB1 1VKX | -8.2 | 1.34 | 0.86 | 0.86 | 0.85 |
| 21 | Galangin | Flavonol | Alpinia galanga | BCL2L1 | -8.4 | 1.28 | 0.86 | 0.86 | 0.85 |
| 22 | Oxyresveratrol | Stilbene | Morus alba | SIRT1 4ZZJ | -8.5 | 1.23 | 0.86 | 0.86 | 0.85 |
| 23 | Withanone | Withanolide | Withania somnifera | NFKB1 1VKX | -8.3 | 1.41 | 0.86 | 0.86 | 0.85 |
| 24 | Oleanolic acid | Triterpenoid | Olea europaea | NLRP3 6NPY | -8.1 | 1.44 | 0.86 | 0.86 | 0.85 |
| 25 | Demethoxycurcumin | Curcuminoid | Curcuma longa | NLRP3 6NPY | -8.4 | 1.33 | 0.86 | 0.86 | 0.85 |
| 26 | Rhamnetin | Flavonol | Syzygium aromaticum | MTOR 4JSV | -8.3 | 1.3 | 0.86 | 0.86 | 0.85 |
| 27 | Jatrorrhizine | Alkaloid | Berberis aristata | FMO3 2VQ7 | -7.8 | 1.37 | 0.86 | 0.85 | 0.86 |
| 28 | Morin | Flavonol | Morus alba | IGF1R 3LVP | -8 | 1.32 | 0.86 | 0.85 | 0.86 |
| 29 | Pinosylvin | Stilbene | Pinus sylvestris | SIRT3 | -8.2 | 1.25 | 0.86 | 0.85 | 0.85 |
| 30 | Betulinic acid | Triterpenoid | Betula utilis | MTOR 4JSV | -8 | 1.46 | 0.86 | 0.85 | 0.85 |
| 31 | Rutin | Flavonol | Fagopyrum esculentum | PIK3CA 4JPS | -8.5 | 1.48 | 0.85 | 0.86 | 0.84 |
| 32 | Hyperoside | Flavonol | Hypericum perforatum | SIRT1 4ZZJ | -8.4 | 1.35 | 0.85 | 0.86 | 0.84 |
| 33 | Isoquercitrin | Flavonol | Emblica officinalis | BCL2L1 | -8.3 | 1.36 | 0.85 | 0.86 | 0.84 |
| 34 | Astragalin | Flavonol | Astragalus membranaceus | FOXO3 | -8 | 1.34 | 0.85 | 0.86 | 0.84 |
| 35 | Gallocatechin | Flavanol | Camellia sinensis | AMPK 4CFE | -8.1 | 1.37 | 0.85 | 0.85 | 0.84 |
| 36 | Taxifolin | Flavanonol | Silybum marianum | NFE2L2 | -7.9 | 1.31 | 0.85 | 0.85 | 0.84 |
| 37 | Naringenin | Flavanone | Citrus limon | SIRT1 4ZZJ | -7.8 | 1.3 | 0.85 | 0.85 | 0.84 |
| 38 | Hesperetin | Flavanone | Citrus aurantium | FOXO3 | -7.9 | 1.32 | 0.85 | 0.85 | 0.84 |
| 39 | Daidzein | Isoflavone | Pueraria tuberosa | IGF1R 3LVP | -7.7 | 1.34 | 0.85 | 0.85 | 0.84 |
| 40 | Biochanin A | Isoflavone | Trifolium pratense | MTOR 4JSV | -7.8 | 1.33 | 0.85 | 0.85 | 0.84 |
| 41 | Formononetin | Isoflavone | Astragalus membranaceus | SIRT1 4ZZJ | -7.7 | 1.35 | 0.85 | 0.85 | 0.84 |
| 42 | Resveratroloside | Stilbene | Polygonum cuspidatum | SIRT1 4ZZJ | -8 | 1.45 | 0.85 | 0.85 | 0.84 |
| 43 | Astringin | Stilbene | Picea abies | SIRT6 3K35 | -8.1 | 1.42 | 0.85 | 0.85 | 0.84 |
| 44 | Isorhapontigenin | Stilbene | Gnetum gnemon | SIRT1 4ZZJ | -8 | 1.26 | 0.85 | 0.85 | 0.84 |
| 45 | Rhapontigenin | Stilbene | Rheum emodi | SIRT3 | -7.9 | 1.27 | 0.85 | 0.84 | 0.85 |
| 46 | Berbamine | Alkaloid | Berberis aristata | NFKB1 1VKX | -8 | 1.48 | 0.85 | 0.84 | 0.85 |
| 47 | Coptisine | Alkaloid | Coptis chinensis | AMPK 4CFE | -7.9 | 1.38 | 0.85 | 0.84 | 0.85 |
| 48 | Magnoflorine | Alkaloid | Tinospora cordifolia | FMO3 2VQ7 | -7.5 | 1.39 | 0.85 | 0.84 | 0.85 |
| 49 | Tetrahydropalmatine | Alkaloid | Corydalis yanhusuo | PADI4 4X8G | -7.6 | 1.4 | 0.85 | 0.84 | 0.84 |
| 50 | Boldine | Alkaloid | Peumus boldus | NLRP3 6NPY | -7.7 | 1.36 | 0.85 | 0.84 | 0.84 |
|
51 |
Evodiamine |
Alkaloid |
Evodia rutaecarpa |
MTOR 4JSV |
-7.9 |
1.37 |
0.85 |
0.84 |
0.84 |
|
52 |
Withanoside IV |
Withanolide |
Withania somnifera |
HSF1 |
-7.8 |
1.5 |
0.85 |
0.84 |
0.84 |
|
53 |
Withanoside V |
Withanolide |
Withania somnifera |
HSF1 |
-7.7 |
1.51 |
0.85 |
0.84 |
0.84 |
|
54 |
Withaferin B |
Withanolide |
Withania somnifera |
NFKB1 1VKX |
-8 |
1.42 |
0.85 |
0.84 |
0.84 |
|
55 |
Withanolide B |
Withanolide |
Withania somnifera |
CDKN2A |
-7.6 |
1.43 |
0.85 |
0.84 |
0.84 |
|
56 |
Withanolide D |
Withanolide |
Withania somnifera |
NFKB1 1VKX |
-7.9 |
1.41 |
0.85 |
0.84 |
0.83 |
|
57 |
12-Deoxywithastramonolide |
Withanolide |
Withania somnifera |
NLRP3 6NPY |
-7.8 |
1.44 |
0.85 |
0.83 |
0.84 |
|
58 |
Asiatic acid |
Triterpenoid |
Centella asiatica |
SIRT3 |
-7.9 |
1.45 |
0.85 |
0.86 |
0.83 |
|
59 |
Madecassic Acid |
Triterpenoid |
Centella asiatica |
PARK2 |
-7.8 |
1.46 |
0.85 |
0.86 |
0.83 |
|
60 |
Glycyrrhetinic acid |
Triterpenoid |
Glycyrrhiza glabra |
NFKB1 1VKX |
-7.9 |
1.47 |
0.85 |
0.85 |
0.83 |
|
61 |
Boswellic acid |
Triterpenoid |
Boswellia serrata |
NLRP3 6NPY |
-7.8 |
1.48 |
0.85 |
0.85 |
0.83 |
|
62 |
Lupeol |
Triterpenoid |
Crataeva nurvala |
MTOR 4JSV |
-7.7 |
1.49 |
0.85 |
0.85 |
0.83 |
|
63 |
Friedelin |
Triterpenoid |
Azima tetracantha |
SIRT1 4ZZJ |
-7.6 |
1.5 |
0.85 |
0.85 |
0.83 |
|
64 |
Taraxasterol |
Triterpenoid |
Taraxacum officinale |
FOXO3 |
-7.5 |
1.46 |
0.85 |
0.84 |
0.83 |
|
65 |
Amyrin |
Triterpenoid |
Protium heptaphyllum |
NFE2L2 |
-7.5 |
1.47 |
0.85 |
0.84 |
0.83 |
|
66 |
Limonin |
Limonoid |
Citrus limon |
NLRP3 6NPY |
-7.6 |
1.42 |
0.85 |
0.84 |
0.83 |
|
67 |
Nomilin |
Limonoid |
Citrus aurantium |
PADI4 4X8G |
-7.4 |
1.43 |
0.85 |
0.84 |
0.83 |
|
68 |
Azadirachtin |
Limonoid |
Azadirachta indica |
NFKB1 1VKX |
-7.8 |
1.52 |
0.85 |
0.84 |
0.83 |
|
69 |
Bisdemethoxycurcumin |
Curcuminoid |
Curcuma longa |
NLRP3 6NPY |
-8 |
1.34 |
0.85 |
0.85 |
0.84 |
|
70 |
Tetrahydrocurcumin |
Curcuminoid |
Curcuma longa |
NFE2L2 |
-7.8 |
1.35 |
0.85 |
0.85 |
0.84 |
|
71 |
Arjunolic acid |
Triterpenoid |
Terminalia arjuna |
NOS3 |
-7.7 |
1.45 |
0.85 |
0.85 |
0.84 |
|
72 |
Chebulagic acid |
Tannin |
Terminalia chebula |
SIRT6 3K35 |
-8.2 |
1.55 |
0.85 |
0.86 |
0.84 |
|
73 |
Chebulinic acid |
Tannin |
Terminalia chebula |
SIRT1 4ZZJ |
-8.1 |
1.56 |
0.85 |
0.86 |
0.83 |
|
74 |
Ellagic acid |
Tannin |
Emblica officinalis |
PARK2 |
-7.9 |
1.33 |
0.85 |
0.86 |
0.84 |
|
75 |
Gallic acid |
Phenolic |
Emblica officinalis |
SIRT1 4ZZJ |
-6.8 |
1.2 |
0.85 |
0.86 |
0.83 |
|
76 |
Corilagin |
Tannin |
Phyllanthus emblica |
NLRP3 6NPY |
-8 |
1.54 |
0.85 |
0.85 |
0.84 |
|
77 |
Geraniin |
Tannin |
Geranium thunbergii |
FMO3 2VQ7 |
-7.6 |
1.53 |
0.85 |
0.85 |
0.84 |
|
78 |
Punicalagin |
Tannin |
Punica granatum |
SIRT3 |
-7.9 |
1.58 |
0.85 |
0.85 |
0.84 |
|
79 |
Withacoagin |
Withanolide |
Withania coagulans |
HSF1 |
-7.5 |
1.44 |
0.85 |
0.84 |
0.83 |
|
80 |
Ashwagandhanolide |
Withanolide |
Withania somnifera |
NFKB1 1VKX |
-7.6 |
1.45 |
0.85 |
0.84 |
0.83 |
|
81 |
Bacopaside A |
Saponin |
Bacopa monnieri |
FOXO3 |
-7.4 |
1.6 |
0.85 |
0.84 |
0.83 |
|
82 |
Bacoside A3 |
Saponin |
Bacopa monnieri |
SIRT1 4ZZJ |
-7.5 |
1.61 |
0.85 |
0.84 |
0.83 |
|
83 |
Ginsenoside Rg1 |
Saponin |
Panax ginseng |
PRKAA1 4CFE |
-7.6 |
1.62 |
0.85 |
0.84 |
0.83 |
|
84 |
Ginsenoside Rb1 |
Saponin |
Panax ginseng |
SIRT1 4ZZJ |
-7.4 |
1.63 |
0.85 |
0.84 |
0.83 |
|
85 |
Diosgenin |
Saponin |
Dioscorea villosa |
MTOR 4JSV |
-7.5 |
1.48 |
0.85 |
0.84 |
0.83 |
|
86 |
Shatavarin IV |
Saponin |
Asparagus racemosus |
FOXO3 |
-7.3 |
1.64 |
0.85 |
0.84 |
0.82 |
|
87 |
Andrographolide |
Diterpenoid |
Andrographis paniculata |
NFKB1 1VKX |
-7.8 |
1.38 |
0.85 |
0.85 |
0.83 |
|
88 |
Forskolin |
Diterpenoid |
Coleus forskohlii |
PRKAA1 4CFE |
-7.5 |
1.39 |
0.85 |
0.84 |
0.83 |
|
89 |
Carnosic acid |
Diterpenoid |
Rosmarinus officinalis |
NFE2L2 |
-7.6 |
1.36 |
0.85 |
0.84 |
0.83 |
|
90 |
Tanshinone IIA |
Diterpenoid |
Salvia miltiorrhiza |
MTOR 4JSV |
-7.7 |
1.37 |
0.85 |
0.84 |
0.83 |
|
91 |
Catechin |
Flavanol |
Acacia catechu |
SIRT1 4ZZJ |
-7.6 |
1.29 |
0.85 |
0.85 |
0.83 |
|
92 |
Epicatechin |
Flavanol |
Theobroma cacao |
NOS3 |
-7.4 |
1.3 |
0.85 |
0.85 |
0.82 |
|
93 |
Procyanidin B2 |
Flavanol |
Vitis vinifera |
SIRT6 3K35 |
-8 |
1.57 |
0.85 |
0.85 |
0.83 |
|
94 |
Silymarin |
Flavonolignan |
Silybum marianum |
NFE2L2 |
-7.8 |
1.53 |
0.85 |
0.85 |
0.83 |
|
95 |
Baicalein |
Flavone |
Scutellaria baicalensis |
PADI4 4X8G |
-7.9 |
1.31 |
0.85 |
0.85 |
0.83 |
|
96 |
Wogonin |
Flavone |
Scutellaria baicalensis |
CDKN2A |
-7.7 |
1.32 |
0.85 |
0.85 |
0.83 |
Table 7: All 96 compounds output table ms>0.85 computational ranking only.
Novel combination INP-AGE-01: Computational coverage
Combination designed on module complementarity: Fisetin 20% +resveratrol+ berberine +urolithin A+withaferin A low-dose, MS average 0.92. Computational putative synergy: Fisetin senolytic via BCL2L1 removes senescent cells, resveratrol restores SIRT1/SIRT3/ AMPK/FOXO3/NOS3/KLF2 (Module 2 glycocalyx), berberine restores AMPK and suppresses MTOR/IGF1R/NLRP3/FMO3/TMAO via gut remodeling, urolithin A restores PARK2 mitophagy (Module 2 + mito), withaferin A suppresses NFKB1/NLRP3/CDKN2A and activates HSF1 (Module 3+proteostasis). Mimics crocodile/shark profile low MTOR, high SIRT/AMPK, low NLRP3. Module coverage comparison computational putative: Classical rapamycin+dasatinib +quercetin covers Module 1 100%+Module 2 20%+Module 3 60%=average 60%, with 0% for four missed pathways=total normalized 0.25. INP-AGE-01 covers Module 1 100% via berberine MTOR/IGF1R, Module 2 100% via resveratrol SIRT1/SIRT3/FOXO3, berberine AMPK/NFE2L2, urolithin A PARK2/SIRT3, withaferin A HSF1, and Module 3 100% via fisetin CDKN2A/BCL2L1, withaferin A NFKB1/NLRP3/CDKN2A, berberine NLRP3/FMO3 urolithin A mitochondrial, average 100%+4/4 missed pathways=normalized 1.0. Provides quantitative evidence of network superiority but remains computational ranking only. Computational bleeding risk low because PADI4/TMAO/PARK2 modulation does not target classical coagulation factors F2/F10 unlike heparin, requiring TEG validation.
Discussion
This study decodes the apex predator lifespan paradox through an 11-layer INP platform [39-44]. Big data correlation revealed log10 max lifespan negatively correlates with BMR (r=-0.81, R2=0.66) and MTOR (r=-0.72) and positively with SIRT6 (r=+0.74) PRKAA1 (r= +0.69) and FOXO3 (r=+0.65). Multiple regression BMR+MTOR +SIRT6+FOXO3+FMO3 explained 78% variance (R2=0.78), advancing rate-of-living. High MTOR/IGF1 supports burst power but accelerates aging via ULK1 autophagy suppression, ROS via NOX, DNA damage, telomere attrition, FOXO3 suppression and AMPK suppression. Crocodile/shark adaptations include: (i) SIRT6 hyperactivity, (ii) Regulated TERT, (iii) Efficient proteostasis via HSF1/HSPA1A, (iv) low FMO3/TMAO, (v) Q10 effect in Greenland shark. In ayurvedic correlation, Jara Swabhavika Vyadhi with Vata 0.90, Pitta 0.85, Kapha Avarana 0.80. Lion/tiger high MTOR +2.3, IGF1 +1.8, NFKB1 +1.5, low SIRT6 -1.2, FOXO3 -1.0 represent Vata-Pitta Prakopa with Kapha Avarana and Alpayu, while crocodile low MTOR -2.0, high SIRT6 +2.0, FOXO3 +1.5, PARK2 +1.3, HSF1 +1.2 represents Kapha Pradhana Deerghayu with balanced Ojas [45]. Failure node analysis distinguishes hyperactive vs. loss, missed by degree-only pharmacology. MCODE three modules correspond to Growth, Longevity and Senescence-Inflammo-SASP-NETs- Glycocalyx-TMAO-Mito. Classical D+Q covers 60% modules, 0% missed pathways, as shown in diabetic kidney and IPF pilots. INPAGE- 01 computationally covers 3/3+4/4=1.0. Four missed pathways bridge inflammaging, immunothrombosis, endothelial and mitochondrial senescence as unified failure network first reported by INP: NETs-immunosenescence, glycocalyx, TMAO-platelet-mito axis mitochondrial senescence. Top compounds MS>0.85 represent first ayurveda-integrated quantitative ranking. Mechanisms: resveratrol/ pterostilbene SIRT1 allosteric activators berberine AMPK activator via Complex I withaferin A NFKB1 inhibitor via IKK and HSF1 activator, urolithin A PINK1-Parkin mitophagy inducer. INP-AGE-01 mimics crocodile/shark low MTOR, high SIRT6/AMPK/FOXO3/ PARK2/HSF1, low NLRP3/FMO3/PADI4, with low bleeding risk because PADI4/TMAO/PARK2 avoids F2/F10. Limitations: All results computational, no biological activity claim. KEGG mapping putative no P-value/FDR. Docking ranking not affinity, requires SPR/ITC/ CETSA. SRA meta-analysis batch effects. Mother Score weighting empirical. No in vitro/in vivo validation yet. Hypothesis-generating.
Conclusion
This research presents INP, an 11-layer platform integrating 1,847 species big data, 168 aging genes, 610K natural products and Ayurvedic Prakriti. It provides a quantitative model explaining lion/ tiger short vs. crocodile/shark long lifespan paradox via five-factor switch (BMR+MTOR+SIRT6+FOXO3+FMO3, R2=0.78) and three modules plus four missed pathways (NETs, glycocalyx, TMAO, mitochondrial senescence). It prioritizes 96 compounds (MS>0.85) and INP-AGE-01 covering 3/3 modules + 4/4 pathways (1.0 vs. 0.25 classical). All findings computational rankings requiring validation by SPR/ITC/CETSA, SA-β-gal, p16, DNAm clock, TRAP, TEM glycocalyx, TMAO LC-MS and aged mouse lifespan.
Acknowledgments
We acknowledge GeneCards, DisGeNET, CTD, LOTUS, COCONUT, AnAge, GTEx, STRING, KEGG, PDB, PubChem, SwissADME, pkCSM, SwissTargetPrediction, SEA, AutoDock Vina developers. No funding to declare.
Conflict of Interest
Authors declare no conflict of interest. This is a computational study, not a clinical recommendation.
References
- Agnivesha Charaka Samhita, Vimana Sthana, Chapter 8. Description of Prakriti, Sara, Samhanana and Deerghayu/Alpayu. Varanasi: Chaukhambha Orientalia.
- Sharangadhara. Sharangadhara Samhita, Purva Khanda, Chapter 6. Description of Jara as Swabhavika Vyadhi and Rasayana-Vayasthapana. Chaukhambha.
- Lopez-Otin C, Blasco MA, Partridge L, Serrano M, Kroemer G (2013) The hallmarks of aging. Cell 153: 1194-1217.
[Crossref] [Google Scholar] [PubMed]
- Lopez-Otin C, Blasco MA, Partridge L, Serrano M, Kroemer G (2023) Hallmarks of aging: An expanding universe. Cell 186: 243-278.
[Crossref] [Google Scholar] [PubMed]
- Tacutu R, Thornton D, Johnson E, Budovsky A, Barardo D, et al. (2018) Human ageing genomic resources: New and updated databases. Nucleic Acids Res 46: D1083-D1090.
[Crossref] [Google Scholar] [PubMed]
- Nielsen J, Hedeholm RB, Heinemeier J, Bushnell PG, Christiansen JS, et al. (2016) Eye lens radiocarbon reveals centuries of longevity in the Greenland shark (Somniosus microcephalus). Science 353: 702-704.
[Crossref] [Google Scholar] [PubMed]
- Keane M, Semeiks J, Webb AE, Li YI, Quesada V, et al. (2015) Insights into the evolution of longevity from the bowhead whale genome. Cell Rep 10: 112-122.
[Crossref] [Google Scholar] [PubMed]
- Tian X, Firsanov D, Zhang Z, Cheng Y, Luo L, et al. (2019) SIRT6 is responsible for more efficient DNA double-strand break repair in long-lived species. Cell 177: 622-638.e22.
[Crossref] [Google Scholar] [PubMed]
- Williams GC (1957) Pleiotropy, natural selection, and the evolution of senescence. Evolution 11: 398-411.
- Kirkwood TB (1977) Evolution of ageing. Nature 270: 301-304.
[Crossref] [Google Scholar] [PubMed]
- Rubner M (1908) Das Problem der Lebensdauer und seine Beziehungen zu Wachstum und Ernährung. Oldenbourg.
- Horvath S (2013) DNA methylation age of human tissues and cell types. Genome Biol 14: R115.
[Crossref] [Google Scholar] [PubMed]
- Yousefzadeh MJ, Zhu YI, McGowan SJ, Angelini L, Fuhrmann-Stroissnigg H, et al. (2018) Fisetin is a senotherapeutic that extends health and lifespan. EBioMedicine 36: 18-28.
[Crossref] [Google Scholar] [PubMed]
- Hickson LJ, Prata LG, Bobart SA, Evans TK, Giorgadze N, et al. (2019) Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of dasatinib plus quercetin in individuals with diabetic kidney disease. EBioMedicine 47: 446-456.
[Crossref] [Google Scholar] [PubMed]
- Justice JN, Nambiar AM, Tchkonia T, LeBrasseur NK, Pascual R, et al. (2019) Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study. EBioMedicine 40: 554-563.
[Crossref] [Google Scholar] [PubMed]
- Kanehisa M, Goto S (2000) KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res 28: 27-30.
[Crossref] [Google Scholar] [PubMed]
- Szklarczyk D, Kirsch R, Koutrouli M, Nastou K, Mehryary F, et al. (2023) The STRING database in 2023: Protein-protein association networks. Nucleic Acids Res 51: D638-D646.
[Crossref] [Google Scholar] [PubMed]
- Bader GD, Hogue CW (2003) An automated method for finding molecular complexes in large protein interaction networks. BMC Bioinformatics 4: 2.
[Crossref] [Google Scholar] [PubMed]
- Eberhardt J, Santos-Martins D, Tillack AF, Forli W (2021) AutoDock Vina 1.2.0: New docking methods, expanded force field, and Python bindings. J Chem Inf Model 61: 3891-3898.
[Crossref] [Google Scholar] [PubMed]
- Trott O, Olson AJ (2010) AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function. J Comput Chem 31: 455-461.
[Crossref] [Google Scholar] [PubMed]
- Daina A, Michielin O, Zoete V (2017) SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness. Sci Rep 7: 42717.
- Pires DE, Blundell TL, Ascher DB (2015) pkCSM: Predicting small-molecule pharmacokinetic and toxicity properties using graph-based signatures. J Med Chem 58: 4066-4072.
- Daina A, Michielin O, Zoete V (2019) SwissTargetPrediction: Updated data and new features for efficient prediction of protein targets. Nucleic Acids Res 47: W357-W364.
- Keiser MJ, Roth BL, Armbruster BN, Ernsberger P, Irwin JJ, et al. (2007) Relating protein pharmacology by ligand chemistry. Nat Biotechnol 25: 197-206.
- Safran M, Rosen N, Twik M, BarShir R, Stein TI, et al. (2016) The genecards suite. Curr Protoc Bioinformatics 54: 1.30.1-1.30.33.
- Pinero J, Ramirez-Anguita JM, Sauch-Pitarch J, Ronzano F, Centeno E, et al. (2020) The DisGeNET knowledge platform for disease genomics: 2019 update. Nucleic Acids Res 48: D845-D855.
- Davis AP, Grondin CJ, Johnson RJ, Sciaky D, McMorran R, et al. (2019) The comparative toxicogenomics database: Update 2019. Nucleic Acids Res 47: D948-D954.
- Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, et al. (2018) DrugBank 5.0: A major update to the DrugBank database for 2018. Nucleic Acids Res 46: D1074-D1082.
- Sorokina M, Steinbeck C (2021) COCONUT online: Collection of open natural products database. J Cheminform 13: 2.
- Zeng X, Zhang P, He W (2023) LOTUS: The natural products occurrence database. Nucleic Acids Res.
- GTEx Consortium (2013) The Genotype-Tissue Expression (GTEx) project. Nat Genet 45: 580-585.
- Kaplan MJ, Radic M (2020) Neutrophil extracellular traps and immunothrombosis. Nat Rev Immunol.
- Reitsma S, Slaaf DW, Vink H, van Zandvoort MA, Oude Egbrink MG (2007) The endothelial glycocalyx: Composition, functions, and visualization. Pflugers Arch 454: 345-359.
- Wang Z, Klipfell E, Bennett BJ, Koeth R, Levison BS, et al. (2011) Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 472: 57-63.
- Tang WW, Wang Z, Levison BS, Koeth RA, Britt EB, et al. (2013) Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N Engl J Med 368: 1575-1584.
- Andreux PA, Blanco-Bose W, Ryu D, Burdet F, Ibberson M, et al. (2019) The mitophagy activator urolithin A is safe and induces a molecular signature of improved mitochondrial health in humans. Nat Metab 1: 595-603.
- Xu X. Berberine activates LKB1-AMPK-TORC2 and AMPK/SIRT1/PGC-1a pathways and modulates gut microbiome and FMO3/TMAO. J Ethnopharmacol.
- White PT, Subramanian C, Motiwala HF, Cohen MS (2016) Natural withanolides in the treatment of chronic diseases. Adv Exp Med Biol.
- Altenhoff AM, Train CM, Gilbert KJ (2024) OMA orthology in 2024. Nucleic Acids Res.
- Barrett T, Wilhite SE, Ledoux P (2013) NCBI GEO: Archive for functional genomics data sets. Nucleic Acids Res.
- Burley SK, Berman HM, Bhikadiya C, Bi C, Chen L, et al. (2021) RCSB Protein data bank: Biological macromolecular structures enabling research and education. Nucleic Acids Res 49: D437-D451.
- O'Boyle NM, Banck M, James CA, Morley C, Vandermeersch T, et al. (2011) Open Babel: An open chemical toolbox. J Cheminform 3: 33.
- Morris GM, Huey R, Lindstrom W (2009) AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J Comput Chem.
- Shannon P, Markiel A, Ozier O (2003) Cytoscape: A software environment for integrated models of biomolecular interaction networks. Genome Res.
- Government of India, Ministry of AYUSH. The ayurvedic formulary of India, Parts I-III. Traditional use only reference for Rasayana herbs: Amalaki, Ashwagandha, Guduchi, Haritaki, Yashtimadhu.
Spanish
Chinese
Russian
German
French
Japanese
Portuguese
Hindi 
